Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRS-033 in healthy volunteers
NCT05724797Phase 1Completed
- Sponsor
- Nirsum Laboratories
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing NRS-033: Cohorts 1-3 with Placebo: Cohorts 1-3 (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 15 months, Severity of Treatment Emergent Adverse Events at 15 months and 11 more. Started Apr 2023; status: completed.
02
Drugs
nalmefene prodrug
Beyond the preview
Go deeper on NCT05724797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724797.